Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

57.35
+0.59001.04%
Post-market: 42.80-14.5500-25.37%19:24 EDT
Volume:1.83M
Turnover:98.69M
Market Cap:5.54B
PE:-12.19
High:58.15
Open:57.60
Low:56.87
Close:56.76
52wk High:72.66
52wk Low:35.97
Shares:96.64M
Float Shares:95.45M
Volume Ratio:3.06
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:4.46
PE(LYR):-13.14

Loading ...

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

Dow Jones
·
18 mins ago

Xenon Pauses New Enrollment in Depression, Bipolar Disorder Trials over Side-Effect Concerns

Reuters
·
2 hours ago

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Reuters
·
2 hours ago

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Reuters
·
3 hours ago

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS
·
3 hours ago

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS
·
3 hours ago

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS
·
3 hours ago

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS
·
3 hours ago

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Dow Jones
·
Sep 11

Wells Fargo Sticks to Its Buy Rating for Xenon (XENE)

TIPRANKS
·
Sep 02

Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33

Reuters
·
Sep 01

Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike

Reuters
·
Aug 29

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 29

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 29

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Simply Wall St.
·
Aug 19

Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550

Reuters
·
Aug 14

J.P. Morgan Remains a Buy on Xenon (XENE)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)

TIPRANKS
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

TIPRANKS
·
Aug 08

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

MT Newswires Live
·
Aug 08